Ascendis Pharma A/S (ASND)

DK — Healthcare Sector
Peers: APLS  BGNE  AKRO  BPMC  REPL  NUVL  VTYX  UTHR  ISEE  AMLX  KRTX  DAWN  KDNY  DICE  PLRX  CRNX  ETNB  MDGL  ACLX  STOK 

Automate Your Wheel Strategy on ASND

With Tiblio's Option Bot, you can configure your own wheel strategy including ASND - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ASND
  • Rev/Share 6.1431
  • Book/Share -3.1625
  • PB -45.2867
  • Debt/Equity -4.4639
  • CurrentRatio 1.0406
  • ROIC -0.5064

 

  • MktCap 8646560072.656
  • FreeCF/Share -5.1255
  • PFCF -28.1076
  • PE -25.1577
  • Debt/Assets 0.7982
  • DivYield 0
  • ROE 1.9142

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade ASND Morgan Stanley Equal Weight Overweight -- $250 May 5, 2025
Initiation ASND RBC Capital Mkts -- Outperform -- $205 April 16, 2025
Initiation ASND UBS -- Buy -- $196 Jan. 7, 2025
Upgrade ASND Oppenheimer Perform Outperform -- $180 Sept. 5, 2024

News

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
ASND
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Negative

Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

Read More
image for news Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
ASND
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive

Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Read More
image for news Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
ASND
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.

Read More
image for news Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
ASND
Published: February 13, 2025 by: Benzinga
Sentiment: Positive

On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros.

Read More
image for news Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
ASND
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Chief Business Officer Jay Wu - President, U.S. Market Aimee Shu - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark-Gartner - Evercore ISI Li Watsek - Cantor Fitzgerald Yaron Werber - TD Cowen Joori Park - Leerink Kelly Shi - Jefferies Ellie Merle - UBS David Lebowitz - Citi Paul Choi - Goldman Sachs Alex Thompson - Stifel …

Read More
image for news Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
ASND
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million

Read More
image for news Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

About Ascendis Pharma A/S (ASND)

  • IPO Date 2015-01-28
  • Website https://ascendispharma.com
  • Industry Biotechnology
  • CEO Mr. Jan Moller Mikkelsen
  • Employees 1017

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.